Immunohistochemistry corroborated the biostatistical findings showing that CRC samples, from short-term survivors, contained an average percentage of EOMES/T-bet double positive cells, and of PD-L1 and TRAF1 positive cells, that was considerably higher (p<0.0001) than in CRC samples from long-term survivors (Table 6 and Figures 2E–H). This evidence concerns the gene TRAF1 and colorectal carcinoma.